Meet Thomas Ray, Senior Scientist at MapLight Therapeutics, Inc.! Tom is a molecular biologist with deep expertise in gene expression analysis and spatial transcriptomics. At MapLight, he and his team are working to identify circuit-targeted therapeutic strategies for CNS disorders. We’re excited to have Tom on board as we continue to push the boundaries of neuroscience research. www.maplightrx.com #TeamSpotlight #CNSResearch #MolecularBiology #MapLightTherapeutics
MapLight Therapeutics, Inc.
Biotechnology Research
Palo Alto, CA 9,278 followers
Creating breakthrough innovative therapeutics for serious CNS disorders
About us
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
- Website
-
http://maplightrx.com
External link for MapLight Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Palo Alto, CA
- Type
- Privately Held
Locations
-
Primary
Palo Alto, CA, US
-
Boston, Massachusetts, US
Employees at MapLight Therapeutics, Inc.
Updates
-
October is Depression Awareness Month. At MapLight Therapeutics, Inc., we are advancing research of potential new treatments for depression. Learn about us and discover more about our commitment to addressing central nervous system disorders. www.maplightrx.com #DepressionAwarenessMonth #MentalHealth #MapLightTherapeutics
-
At MapLight Therapeutics, Inc., we’re pushing the boundaries of scientific discovery. 🔬 Our platform, featuring STARmap spatial transcriptomics, is just one example of how we’re leveraging innovative technologies to advance our research. With STARmap technology, hundreds of gene transcripts can be assayed in situ, preserving the spatial integrity and anatomical architecture of brain circuits. Curious to learn more about our platform? Visit our website. https://lnkd.in/gudWcFta #STARMap #RNA #Research #Platform
-
Join us in welcoming our newest team members to MapLight! We’re thrilled to have the following folks on board as we continue to grow and innovate in the field of Central Nervous System disorder research: ⭐️ Samantha Koth, Executive Director, Medical Affairs ⭐️ Faye Lytle MS, Lead CRA ⭐️ Chia Ogbonnaya, Senior CRA ⭐️ Ron Valdez, Senior CRA Looking forward to the amazing contributions you all will bring to the team! #NewHires #EmployeeFeatures #LifeAtMapLight #CompanyGrowth
-
Looking for a new opportunity? MapLight is growing, and we’re looking for talented individuals to join our team. Explore career opportunities in various roles across the company and be part of a team dedicated to making a difference in the lives of those with brain disorders. Check out our open positions today – and remember, if there isn't a perfect-fit role open now, you can always apply to our open position role. We'll keep your resume on file. https://lnkd.in/dgHz9Mrx #Careers #Hiring #OpenPositions #OpenRoles #JobOpenings
-
Meet Andy Czysz, our Senior Medical Director of Clinical Development at MapLight Therapeutics, Inc. Andy joined our team because he believes in the immense potential of a circuit-based approach to drug discovery for CNS disorders. His expertise is instrumental as we work towards our goal of developing novel treatments. Learn more about our work. www.maplightrx.com #EmployeeSpotlight #MeetTheTeam #MapLightTherapeutics
-
The MapLight team had a wonderful time at Autism Acceptance Night with the San Francisco Giants on August 30. The evening was a special opportunity to raise awareness and promote acceptance for the Autism community. A big thank you to Will Clark and his family for hosting, and to everyone who joined us for making this night truly memorable. We look forward to next year! #AutismAcceptance #SFGiants #CommunitySupport #AutismSpectrumDisorder #LifeAtMapLight
-
MapLight Therapeutics, Inc. reposted this
Preparations are in full swing for the 7th Neuropsychiatric Drug Development Summit, kicking off in 3 weeks to fuel the next generation of neuropsychiatry approvals. Here’s what’s in store for you: 🌟Share cutting-edge advancements and foster pre-competitive collaboration to innovate precision psychiatry, propel next-generation drug R&D, and fuel more clinical approvals 🗨️ Engage in interactive panel discussions on transforming ‘precision neuropsychiatry’ from idea to realization with Alto Neuroscience, Delix Therapeutics, Compass Pathways, Boehringer Ingelheim 🔍 Discover new next-generation targets, modalities, and technologies from 8+ new presenting companies, including Karuna Therapeutics, Click Therapeutics, Inc. MapLight Therapeutics, Inc., and Sensorium Therapeutics Have a look at the agenda for more detail: https://ter.li/ecg8eq And a big thanks to the partners! Biotrial www.biotrial.com Centre for Human Drug Research www.CHDR.nl bit.bio www.bit.bio Eurofins www.eurofins.ca Ulysses Neuroscience Limited www.ulysses-neuro.ie Sama Therapeutics www.sama.ac SynapCell www.synapcell.com Advanced Brain Monitoring https://lnkd.in/edkmPsM2
-
September is World Alzheimer’s Month – a time to raise awareness and challenge the stigma surrounding Alzheimer’s disease and all types of dementias. Neuropsychiatric symptoms associated with Alzheimer's disease cause substantial distress for both people with dementia and their caregivers. They are among the earliest signs and symptoms of neurocognitive disorders and cognitive decline, yet are under-recognized and often challenging to treat. Approximately 40% of people living with Alzheimer's experience delusions and hallucinations. MapLight Therapeutics, Inc. is committed to advancing our program for the treatment of Alzheimer's Disease Psychosis. Learn more about our ongoing efforts. https://lnkd.in/d5wESj-M #WorldAlzheimersMonth #AlzheimersAwareness #EndAlz #KnowDementia
-
National Grief Awareness Day (August 30) is dedicated to raising awareness of the myriad ways in which individuals cope with loss. It offers resources to those going through personal losses and reminds us to support people we know who are grieving. Many mental health disorders come with a heightened risk of suicidal thoughts or attempts. We recognize the experience of families and caregivers who have lost a loved one to suicide. At MapLight Therapeutics, we are committed to developing innovative treatments that can improve lives of millions of people living with debilitating mental conditions. https://maplightrx.com/